Treace Medical Concepts, Inc.
TMCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $209 | $187 | $142 | $94 |
| % Growth | 11.9% | 31.9% | 50.2% | – |
| Cost of Goods Sold | $41 | $35 | $28 | $17 |
| Gross Profit | $168 | $152 | $114 | $78 |
| % Margin | 80.4% | 81.2% | 80.6% | 82.1% |
| R&D Expenses | $21 | $15 | $14 | $10 |
| G&A Expenses | $56 | $47 | $33 | $18 |
| SG&A Expenses | $203 | $188 | $138 | $84 |
| Sales & Mktg Exp. | $148 | $141 | $105 | $65 |
| Other Operating Expenses | $0 | $0 | -$2 | $0 |
| Operating Expenses | $224 | $203 | $149 | $94 |
| Operating Income | -$56 | -$51 | -$35 | -$17 |
| % Margin | -26.6% | -27.5% | -24.6% | -17.5% |
| Other Income/Exp. Net | -$0 | $2 | -$8 | -$4 |
| Pre-Tax Income | -$56 | -$50 | -$43 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$56 | -$50 | -$43 | -$21 |
| % Margin | -26.6% | -26.5% | -30.2% | -21.8% |
| EPS | -0.9 | -0.81 | -0.77 | -0.38 |
| % Growth | -11.1% | -5.2% | -102.6% | – |
| EPS Diluted | -0.9 | -0.81 | -0.77 | -0.38 |
| Weighted Avg Shares Out | 62 | 61 | 55 | 54 |
| Weighted Avg Shares Out Dil | 62 | 61 | 55 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $7 | $1 | $0 |
| Interest Expense | $5 | $5 | $4 | $4 |
| Depreciation & Amortization | $8 | $5 | $2 | $1 |
| EBITDA | -$42 | -$39 | -$36 | -$16 |
| % Margin | -20.1% | -20.8% | -25.6% | -16.7% |